Skip to content

Evaluating Adenoma Recurrence After Endoscopic Mucosal Resection With Margin Marking or Post Treatment With Snare Tip Soft Coagulation

Prospective Randomized Controlled Trial Evaluating Adenoma Recurrence After Endoscopic Mucosal Resection With Margin Marking or Post Treatment With Snare Tip Soft Coagulation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06476145
Acronym
ERADICATE
Enrollment
342
Registered
2024-06-26
Start date
2023-12-08
Completion date
2027-01-08
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoma Colon Polyp

Brief summary

Non-inferiority trial comparing the recurrence rate of adenomas in non-pedunculated colonic lesions following endoscopic mucosal resection with margin marking (EMR-MM) and endoscopic mucosal resection with thermal margin ablation (EMR-STSC)

Interventions

None listed

Sponsors

Northwestern University
CollaboratorOTHER
White River Junction Veterans Affairs Medical Center
CollaboratorFED
Rush University
CollaboratorOTHER
University Medical Centre Ljubljana
CollaboratorOTHER
University of Kansas
CollaboratorOTHER
Henry Ford Health System
CollaboratorOTHER
Carilion Clinic
CollaboratorOTHER
St. Paul's Hospital, Canada
CollaboratorOTHER
Minneapolis Veterans Affairs Medical Center
CollaboratorFED
AdventHealth
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. Age 18 years or older 2. Ability to provide informed consent 3. Patient scheduled to undergo colonoscopy for the evaluation and removal of colon polyps 4. Non-pedunculated polyps ≥ 20 mm size

Exclusion criteria

1. Pedunculated polyps 2. Inflammatory bowel disease 3. Inability to provide informed consent 4. Lesions \< 20 mm in size (largest dimension) 5. Lesion involves the lips of the ileocecal valve, is located at the appendiceal orifice and/or is fully circumferential. 6. Any standard contraindication, including pregnancy, to anesthesia and/or colonoscopy

Design outcomes

Primary

MeasureTime frameDescription
Adenoma Reocurrance3 - 12 (+/- 6 months)During Screening Colonoscopy (SC) 1, between 3 -12 post initial procedure. The post-EMR site will be assessed and biopsied for histology to assess for recurrence of adenoma.

Secondary

MeasureTime frameDescription
EMR procedure timeDuring procedure visitTime from submucosal injection to completion of resection, including the time required to treat any intraprocedural adverse event, but not including time on prophylactic endoscopic closure.
Comparison of MM vs STSC procedure timeIndex procedure visitMM procedure time is defined as that required to complete placing cautery marks around the lesion prior to resection. STSC time is defined as that required to complete margin ablation around the entire resection margin.
Incidence of overall severe adverse events: BleedingIndex procedure, 1 - 3 days post, 30 days.Severe bleeding (immediate or delayed): defined as the need for hospitalization, transfusion, repeat endoscopy, surgery or interventional radiology. Immediate complication is defined as an event at the time of ESD resection or immediately following colonoscopy (before patient has left the endoscopy unit or during the immediate post-procedural care). A delayed (post-procedure) bleed is defined as an event that occurs after the patient has left the endoscopy unit and within 30 days following the procedure
Incidence of overall severe adverse events: PerforationIndex procedure, 1 - 3 days post, 30 days.Defined as complete hole, or full-thickness resection of the muscularis propria (Sidney classification of deep mural injury type IV or V).
Incidence of overall severe adverse events: Postpolypectomy SyndromeIndex procedure, 1 - 3 days post, 30 days.Abdominal pain severe enough to warrant emergency room or hospital admission in the presence of fever, leukocytosis, peritoneal inflammation in the absence of frank perforation on CT, and/or required treatment with antibiotics.

Countries

United States

Contacts

Primary ContactDiana Paredes, RN
Diana.Paredes@adventhealth.com407-303-5503
Backup ContactPetronio Martins, MHA
Petronio.martins@adventhealth.com407-303-5503

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026